^
Association details:
| Biomarker: | Chr del(17)(p13) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
Excerpt:
This multicenter, retrospective cohort study examined CLL patients treated with front-line ibrutinib...though progression and/or transformation accounted for a larger proportion of discontinuations in <65 and those with del(17p13). Response rates were similar for <65 and those with del(17p13). However, patients with del(17p13) had inferior PFS and OS.
DOI:
10.1002/ajh.25261
